Overactive Bladder
Methodology & AI Transparency ⓘ
Overactive Bladder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Overactive bladder is a condition in which the bladder squeezes urine out at the wrong time.
- 2 Real-world patient consensus: Diagnostic registry N39.6: Overactive Bladder is managed within Urology & Prostate.
- 3 Typical cash cost range: Clinicians assessing Overactive Bladder focus on uropathogenic bacterial mucosal in Overactive Bladder (N39.6: adherence (cystitis) or) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Overactive Bladder: Total PSA & in Overactive Bladder (N39.6: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N39.6)) and IPSS Urinary Symptom in Overactive Bladder (N39.6: Score).
Ask our AI Specialists anything about Overactive Bladder
What Is Overactive Bladder?
Overactive bladder is a condition in which the bladder squeezes urine out at the wrong time. You may have overactive bladder if you have two or more of these symptoms: You urinate eight or more times a day or two or more times at night You have the sudden, strong need to urinate immediately You leak urine after a sudden, strong urge to urinate You also may have incontinence , a loss of bladder control. Nerve problems, too much fluid, or too much caffeine can cause it. Often the cause is unknown. Your doctor may prescribe a medicine that can calm muscles and nerves. The medicine may come as a pill, a liquid, or a patch. The medicines can cause your eyes to become dry.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Overactive Bladder (ICD-10 N39.6) is driven by uropathogenic bacterial mucosal in Overactive Bladder (N39.6: adherence (cystitis) or); Cross-referenced with NIH MeSH (Urinary Bladder, Overactive), specialists in Prostate (BPH), Bladder & Urinary Tract monitor IPSS Urinary Symptom in Overactive Bladder (N39.6: Score) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • You urinate eight or more times a day or two or more times at night
- • You have the sudden, strong need to urinate immediately
- • Presentation of Overactive Bladder (N39.6): waking two or in Overactive Bladder (N39.6: more times nightly)
- • Secondary Overactive Bladder clinical sign: burning dysuria, suprapubic in Overactive Bladder (N39.6: discomfort, or cloudy/hematuric)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Overactive Bladder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N39.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Total PSA & in Overactive Bladder (N39.6: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N39.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Overactive Bladder (N39.6: Score) | 0 – 7 (mild symptoms) (N39.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Overactive Bladder (N39.6: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N39.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Overactive Bladder
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tolterodine Tartrate Detrol • RxCUI 855178 | Cholinergic Muscarinic Antagonist | 80% | $0.2000 | $ 7.10 /mo |
| Solifenacin Succiate Solifenacin Succinate • RxCUI 477372 | Cholinergic Muscarinic Antagonist | 80% | $0.1816 | $ 15.85 /mo |
| Solifenacin Succinate Vesicare • RxCUI 477367 | Cholinergic Muscarinic Antagonist | 78% | $0.1466 | $ 6.08 /mo |
| Mirabegron Mirabgeorn, Myrbetriq • RxCUI 1300791 | beta3-Adrenergic Agonist | 84% | $9.0229 | $ 185.00 /mo |
| Fesoterodine Fumarate Toviaz • RxCUI 810071 | FDA Prescription Therapeutic Agent | 89% | $0.7765 | $ 39.95 /mo |
| Trospium Chloride Sanctura • RxCUI 857560 | Cholinergic Muscarinic Antagonist | 77% | $0.2068 | $ 9.51 /mo |
| Vibegron Gemtesa • RxCUI 2472315 | beta3-Adrenergic Agonist | 74% | $15.9926 | $ 185.00 /mo |
| Oxybutynin Oxytrol for Women, Oxytrol • RxCUI 863619 | Cholinergic Muscarinic Antagonist | 79% | $0.0817 | $ 6.05 /mo |
| Darifenacin Hydrobromide Darifenacin Hydrobromide Generic • RxCUI 485421 | Cholinergic Muscarinic Antagonist | 80% | $0.5494 | $ 30.75 /mo |
| Gemtesa (Vibegron) Gemtesa • RxCUI 2472321 | beta3-Adrenergic Agonist | 87% | $15.9926 | $ 640.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Overactive Bladder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder: What a 538-Participant Study Found In this post hoc responder analysis from the phase 3 COURAGE trial, participants receiving vibegron vs placebo achieved clinically relevant reductions in bothersome OAB symptoms, as well as improvements in IPSS and OAB-q scores. Urology • 2025-12-15 • Phase III Randomized Trial | N = 538 | 93/100 | PMID 40902908 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of onabotulinumtoxinA in patients with overactive bladder: OnabotulinumtoxinA was efficacious and well tolerated in women and in men with lower PSA levels. International urology and nephrology • 2021-11-15 • Phase III Randomized Trial | N = 186 | 88/100 | PMID 34292493 ↗ |
| Can This Approach Help? Inside the Latest Research on Dexamethasone intraocular suspension 9% on intraocular pressure after routine Dexamethasone intraocular suspension was associated with IOP elevation patterns comparable with applied to the skin prednisolone. Journal of cataract and refractive surgery • 2021-01-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32818346 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of skin-adhesive low-level light therapy for overactive LLLT may be clinically useful and safe for the treatment of OAB. International urogynecology journal • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35389054 ↗ |
| New Insights on Efficacy of mirabegron, a β 3 -adrenoreceptor agonist, in Japanese women with: What a 204-Participant Study Found Mirabegron 50 mg significantly improved key overactive bladder symptoms versus placebo in women with urgency urinary incontinence, and it also improved most overactive bladder symptoms, including micturition frequency, in... International journal of urology : official journal of the Japanese Urological Association • 2022-01-15 • Phase III Randomized Trial | N = 204 | 88/100 | PMID 34605079 ↗ |
Overactive Bladder Patient Community & “People Like Me” Threads
Filter Overactive Bladder community threads and patient logs by age, biological sex, dosage, and treatment duration.